Group One Trading, L.P. Actinium Pharmaceuticals, Inc. Transaction History

Group One Trading, L.P.

  • $2.4 Billion
  • Q3 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024
BUY
$5.0 - $9.2 $87,595 - $161,174
17,519 Added 347.6%
22,559 $176,000
Q4 2023

Feb 14, 2024
BUY
$4.02 - $6.08 $20,260 - $30,643
5,040 New
5,040 $25,000
Q2 2023

Aug 09, 2023
SELL
$7.15 - $9.39 $173,430 - $227,763
-24,256 Reduced 61.15%
15,413 $114,000
Q1 2023

May 12, 2023
BUY
$8.51 - $14.26 $320,461 - $536,988
37,657 Added 1871.62%
39,669 $374,000
Q4 2022

Feb 09, 2023
SELL
$7.05 - $14.41 $495,220 - $1.01 Million
-70,244 Reduced 97.22%
2,012 $21,000
Q3 2022

Nov 09, 2022
BUY
$4.81 - $8.48 $133,645 - $235,616
27,785 Added 62.48%
72,256 $533,000
Q2 2022

Aug 11, 2022
BUY
$4.71 - $7.11 $150,079 - $226,553
31,864 Added 252.75%
44,471 $214,000
Q1 2022

May 12, 2022
BUY
$4.57 - $6.4 $52,756 - $73,881
11,544 Added 1085.98%
12,607 $64,000
Q4 2021

Feb 11, 2022
BUY
$6.01 - $8.8 $6,388 - $9,354
1,063 New
1,063 $6,000
Q2 2021

Aug 10, 2021
SELL
$7.01 - $8.63 $30,738 - $37,842
-4,385 Closed
0 $0
Q1 2021

May 12, 2021
SELL
$7.62 - $9.79 $212,437 - $272,935
-27,879 Reduced 86.41%
4,385 $33,000
Q4 2020

Feb 10, 2021
BUY
$7.8 - $12.64 $230,513 - $373,549
29,553 Added 1090.11%
32,264 $252,000
Q3 2020

Nov 12, 2020
BUY
$7.26 - $18.0 $19,681 - $48,798
2,711 New
2,711 $26,000

Others Institutions Holding ATNM

# of Institutions
74
Shares Held
8.31M
Call Options Held
65.2K
Put Options Held
21.7K
View Full List

About Actinium Pharmaceuticals, Inc.

ATNM Quotes by TradingView
  • Ticker ATNM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,184,700
  • Market Cap $28.2M
  • Description
  • Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...
More about ATNM
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email